Publications by authors named "Y Arinobu"
Objectives: The purpose of the present study was to investigate the differential impact of disease activity and severity on functional status and patient satisfaction in rheumatoid arthritis (RA) using cluster analysis on data from the FRANK registry.
Methods: Data from 3,619 RA patients in the FRANK registry were analysed. Patients were grouped using hierarchical and k-means cluster analyses based on age, physician's global assessment (PhGA), patient's pain assessment (PtPA), and Steinbrocker stage.
Objectives: We aimed to evaluate the effects of age on clinical characteristics and outcomes in biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD)-naïve patients with rheumatoid arthritis (RA).
Methods: We analysed the cases of 234 Japanese b/tsDMARD-naïve RA patients who underwent b/tsDMARD treatment in a multicentre ultrasound prospective observational cohort. We compared the clinical characteristics at baseline and outcomes at 12 months between those aged ≥60 years and those <60 years.
This study aimed to clarify the efficacy and safety of treatment escalation by initiating therapeutic agents in serologically active clinically quiescent (SACQ) patients with systemic lupus erythematosus (SLE). We retrospectively evaluated SACQ patients with SLE for ≥ 180 days, with the introduction of a therapeutic agent for SLE defined as exposure. The efficacy endpoints included the time to flare and time to remission, whereas the safety endpoint was the incidence of adverse events.
View Article and Find Full Text PDFObjective: This study aimed to analyse whether initiating nintedanib treatment at a reduced dose could improve the treatment continuation rate while maintaining efficacy in patients with connective tissue disease (CTD)-associated interstitial lung disease.
Method: In total, 51 patients (age 61.6 ± 13.
Article Synopsis
- Glucocorticoids can effectively treat rheumatoid arthritis (RA) when used at low doses, but their impact on subsequent treatments with biologic and targeted synthetic drugs (b/tsDMARDs) needs evaluation.
- In a study of 307 RA patients, 160 were on glucocorticoids; those treated with these medications showed higher disease activity and less effective treatment responses after 12 months compared to those who were not.
- The findings suggest that patients requiring glucocorticoids may be in poorer health, which could explain their diminished response to b/tsDMARDs, highlighting the need to carefully consider glucocorticoid use during RA treatment.